Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226440 · ClinicalTrials.gov registry record · Phase 1
Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)
A Phase 1 study of Toxicant Exposure and Firefighter, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07226440 is a Phase 1 study of Toxicant Exposure and Firefighter that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07226440, a Phase 1 study of Toxicant Exposure and Firefighter, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, placebo-controlled crossover trial will test the feasibility and acceptability of using colesevelam in male firefighters with high per- and polyfluoroalkyl substances (PFAS) exposure. This trial will also explore whether colesevelam lowers blood PFAS levels and urine environmental toxicant and mold mycotoxin levels.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Colesevelam
Study Locations (1)
California
- UCSF Osher Center for Integrative Health - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226440
The ClinicalTrials.gov registry entry for NCT07226440 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Toxicant Exposure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07226440 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07226440 about?
NCT07226440 is a clinical study titled "Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)". This randomized, placebo-controlled crossover trial will test the feasibility and acceptability of using colesevelam in male firefighters with high per- and polyfluoroalkyl substances (PFAS) exposure. This trial will also explore whether colesevelam lowers blood PFAS levels and urine environmental t...
What is the current status of trial NCT07226440?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-03-01. Estimated completion is 2028-12.
What conditions does trial NCT07226440 study?
This clinical trial studies the following conditions: Toxicant Exposure, Firefighter, Occupational Exposure to Chemicals.
What interventions are being tested in trial NCT07226440?
The interventions under investigation include: Placebo (DRUG), Colesevelam (DRUG).
Who is sponsoring clinical trial NCT07226440?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226440 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.